Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ontamalimab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms FIGARO UC 302
  • Sponsors Shire; Shire Human Genetic Therapies; Takeda

    • Most Recent Events

    • 22 Dec 2021 This trial has been completed in Belgium (End date:2020-10-06), according to European Clinical Trials Database record.
    • 20 Dec 2021 This trial has been completed in Hungary (End date:2020-10-06), according to European Clinical Trials Database record.
    • 27 Oct 2021 Results assessing the clinical remission threshold for the UC e-diary using data from 2 Phase 3 trials (NCT03259334 and NCT03259308) of patients with ulcerative colitis, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top